|
| Figure 1: UFR (μl/kg/min), UNaV (μM/kg/min) and FNaE (%) measurements, during saline (control phase1), PE infusion (phase2) and PE infusion in presence of CEC (phase3) in SHRNNa and SHRHNa group. Data presented as mean ± S.E.M. (n=6) and were analyzed by one-way ANOVA followed by Bonferonni post-hoc test. *indicate p<0.05 between control saline phase1 and agonist PE phase2. |
